Reports Q4 revenue $3.43B, consensus $3.29B. “2023 marked another year of exceptional accomplishments for Regeneron as we further diversified our revenue base and made important progress in our robust R&D pipeline,” said Leonard Schleifer, CEO. “In 2024, we plan to build on this momentum with continued growth of our breakthrough products Dupixent and EYLEA HD while we bring additional new therapies to market and advance our growing pipeline”.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on REGN:
- Linvoseltamab Receives EMA Filing Acceptance for Treatment of Relapsed/Refractory Multiple Myeloma
- Regeneron Announces New CFO and Executive Promotions
- 2seventy Bio upgraded to Outperform at Leerink on acquisition potential
- REGN Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- 2seventy Bio cut to Market Perform at TD Cowen as outlook hinges on Abecma